There are 11 Fast Track Approval as of June 30, 2022 in the year of 2022. They are Pyrukynd (Mitapivat), Vonjo (Pacritinib), Opdualag (Nivolumab and Relatlimab-RMBW), Hyftor (Sirolimus), Igalmi (Dexmedetomidine), Vivjoa (Oteseconazole), Voquezna Triple Pak (Vonoprazan, Amoxicillin, and Clarithromycin), Voquezna Dual Pak (Vonoprazan and Amoxicillin), Radicava Ors (Edaravone), Tpoxx (Tecovirimat) and Amvuttra (Vurisiran).
The treatments of these drug products include: heolytic anemia (with pyruvate kinase deficiency), myelofibrosis with a platelet count below 50 X 10^9/L, metastatic melanoma, facial angiofibroma associated with tuberous sclerosis, agitation associated with schizophrenia, vulvovaginal candidates in females with a history of RVVC who are not of reproductive potential, helicobacter pylori infection, amyotrophic lateral sclerosis, smallpox disease caused by variola virus in adults and pediatric patients weighing at least 3 Kg, polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Thus, most of the treatments are used for certain diseases under certain conditions. Please review the table below:
https://tzpss.blogspot.com/2006/11/cder-fast-track-products-approved-since.html
https://tzpss.blogspot.com/2006/11/cder-fast-track-products-approved-since.html
